A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Launched by HOFFMANN-LA ROCHE · Dec 18, 2007
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-80 years of age;
- • moderate to severe active rheumatoid arthritis;
- • inadequate response to previous or current treatment with 1 anti-TNF agent;
- • receiving methotrexate at a dose of 10-25mg/week for 12 weeks prior to start of study, at a stable dose for \>=4 weeks.
- Exclusion Criteria:
- • previous treatment with MabThera;
- • use of an anti-TNF alpha agent within 8 weeks of study start;
- • concurrent treatment with any DMARD other than methotrexate;
- • active infection, or history of serious recurrent or chronic infection.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kazan, , Russian Federation
Voronezh, , Russian Federation
Moscow, , Russian Federation
Ekaterinburg, , Russian Federation
Kazan, , Russian Federation
Ryazan, , Russian Federation
Yaroslavl, , Russian Federation
Yaroslavl, , Russian Federation
Irkutsk, , Russian Federation
Khabarovsk, , Russian Federation
Nizhny Novgorod, , Russian Federation
Ufa, , Russian Federation
Voronezh, , Russian Federation
Moscow, , Russian Federation
Nizhny Novgorod, , Russian Federation
Kursk, , Russian Federation
Novosibirsk, , Russian Federation
Chelyabinsk, , Russian Federation
Khanty Mansiysk, , Russian Federation
Kursk, , Russian Federation
Saint Petersburg, , Russian Federation
Tjumen, , Russian Federation
Vladivostok, , Russian Federation
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials